Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) and Lymphocyte to Monocyte Ratio (LMR) in Newly Diagnosed Advanced-Stage Hodgkin Lymphoma Patients Treated up-Front with a PET-2 Risk Adapted Protocol

Blood (2018) 132 (Supplement 1): 2934.

https://doi.org/10.1182/blood-2018-99-115346

Published: 2018

Journal Articles

Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma

Blood (2018) 131 (22): 2454–2465.

https://doi.org/10.1182/blood-2017-11-814913

Published: 2018

Includes: Supplemental data

Journal Articles

Molecular Definition of Activated B Cell-like (ABC) DLBCL Identifies Patients Who May Benefit from Front-Line Intensive R-HDS Chemotherapy with ASCT

Federica Melle, Giovanna Motta, Marco Fabbri, Valentina Tabanelli, MD, Angelica Calleri, PhD, Riccardo Bruna, Enrico Derenzini, MD PhD, Chiara Corsini, Corrado Tarella, MD Prof, Alessandro M. Gianni, MDProf, Alessandro Rambaldi, MD Prof, Alessandra Cesano, Stefano A. Pileri

Blood (2017) 130 (Supplement 1): 3998.

https://doi.org/10.1182/blood.V130.Suppl_1.3998.3998

Published: 2017

Journal Articles

Early Reduction of Serum TARC Levels Predicts Prognosis of Patients Treated with a PET-Adapted Strategy for Advanced Stage Hodgkin Lymphoma (HL) in the GITIL/FIL HD0607 Trial

Blood (2017) 130 (Supplement 1): 1511.

https://doi.org/10.1182/blood.V130.Suppl_1.1511.1511

Published: 2017

Journal Articles

New Recurrently Mutated Genes in Classical Hodgkin Lymphoma Revealed By Whole-Exome Sequencing of Microdissected Tumor Cells

Enrico Tiacci#, Alexander Penson#, Gianluca Schiavoni#, Erik Ladewig#, Elisabetta Fortini#, Yuchun Wang, Ariele Spanhol-Rosseto, Alessandra Venanzi, Alessandro M. Gianni, Simonetta Viviani, MD, Antonello Cabras, Barbara Crescenzi, Cristina Mecucci, MD PhD, Laura Pasqualucci°, Raul Rabadan°, Brunangelo Falini°

Blood (2016) 128 (22): 1088.

https://doi.org/10.1182/blood.V128.22.1088.1088

Published: 2016

Journal Articles

TARC before ASCT Is Highly Predictive of Outcome in Patients with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) after First-Line Therapy

Simonetta Viviani, MD, Francesco Spina, MD, Arabella Mazzocchi, Maria Galbiati, Flavio Crippa, MD, Lucia Farina, MD PhD, Anna Guidetti, MD, Massimo Di Nicola, Liliana Franca Devizzi, MD, Paola Matteucci, MD, Michele Magni, MD, Anna Dodero, Alessandro M. Gianni, MD, Paolo Corradini, MD

Blood (2016) 128 (22): 3009.

https://doi.org/10.1182/blood.V128.22.3009.3009

Published: 2016

Journal Articles

Late Relapse in Hodgkin Lymphoma (HL): A Retrospective Analysis of Patients Enrolled on Clinical Trials at the Istituto Nazionale Tumori of Milan (INT-MI)

Simonetta Viviani, MD, Alberto Mussetti, MD, Oreste Di Bartolo, MD, Antonello Cabras, MD, Pinuccia Valagussa, Statistician, Gianni Bonadonna, MD, Alessandro M. Gianni, MD, Paolo Corradini, MD

Blood (2015) 126 (23): 2697.

https://doi.org/10.1182/blood.V126.23.2697.2697

Published: 2015

Journal Articles

HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma

Roberta Zappasodi, Giusi Ruggiero, Carla Guarnotta, Monica Tortoreto, Cristina Tringali, Alessandra Cavanè, Antonello D. Cabras, Lorenzo Castagnoli, Bruno Venerando, Nadia Zaffaroni, Alessandro M. Gianni, Filippo De Braud, Claudio Tripodo, Serenella M. Pupa, Massimo Di Nicola

Blood (2015) 125 (11): 1768–1771.

https://doi.org/10.1182/blood-2014-07-590034

Published: 2015

Includes: Supplemental data

Journal Articles

The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

Craig H. Moskowitz, MD, Auayporn Nadamanee, MD, Tamas Masszi, MD PhD, Edward Agura, MD, Jerzy Holowiecki, MD PhD, Muneer H. Abidi, MD, Andy I Chen, MDPhD, Patrick J. Stiff, MD, Alessandro M. Gianni, MD, Angelo M. Carella, MD, Dzhelil Osmanov, MD, Veronika Bachanova, MD, John Sweetenham, MD, Anna Sureda, Dirk Huebner, MD, Emily K. Larsen, MS, Naomi N.H. Hunder, MD, Jan Walewski

Blood (2014) 124 (21): 673.

https://doi.org/10.1182/blood.V124.21.673.673

Published: 2014

Journal Articles

Brentuximab Vedotin (BV) an Effective Treatment for Autologous (ASCT) and/or Allogeneic (alloSCT) Transplant naïve Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) : A retrospective Single-Institution Study

Simonetta Viviani, MD, Serena Dalto, MD, Paola Matteucci, MD, Massimo Di Nicola, MD, Anna Guidetti, MD, Liliana Devizzi, MD, Michele Magni, MD, Anna Dodero, MD, Lucia Farina, MD, Francesco Spina, MD, Alessandro M. Gianni, MD, Paolo Corradini, MD

Blood (2014) 124 (21): 5428.

https://doi.org/10.1182/blood.V124.21.5428.5428

Published: 2014

Journal Articles

Potent In Vivo Anti-Tumor Activity Of Extracellular Vesicles Isolated From Genetically Engineered Primary Mesenchymal Stromal Cells Expressing The Trans-Membrane TNF-Related Apoptosis-Inducing Ligand (TRAIL)

Stefano Buttiglieri, PhD, Carmelo Carlo-Stella, MD, Tiziana Spatola, BiolSc, Roberta Pulito, BiolSc, Luigi Naldini, MD, PhD, Andrea Anichini, PhD, Michele Magni, MD, Arianna Giacomini, PhD, Corrado Tarella, MD, Alessandro M. Gianni, MD

Blood (2013) 122 (21): 1658.

https://doi.org/10.1182/blood.V122.21.1658.1658

Published: 2013

Journal Articles

The Peripheral Blood Lymphocyte to Monocyte Ratio At Diagnosis Is a Potent Outcome Predictor in Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Long-Term Analysis On 973 Patients Receiving Chemotherapy with or without Rituximab

Alessandro Rambaldi, MD, Cristina Boschini, Federica Delaini, BiolSC, Elena Oldani, BiolSC, Andrea Rossi, MD, Anna Maria Barbui, MD, Giuseppe Gritti, MD, Daniele Caracciolo, MD, Marco Ladetto, MD, Angela Gueli, MD, Alberto De Crescenzo, MD, Roberto Passera, PhD, Liliana Devizzi, MD, Alessandro M. Gianni, MD, Corrado Tarella, MD

Blood (2012) 120 (21): 1553.

https://doi.org/10.1182/blood.V120.21.1553.1553

Published: 2012

Journal Articles

The histone Deacetylase Inhibitor Givinostat in Combination with Sorafenib Induces Reactive Oxygen Species (ROS) Generation and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts

Silvia L Locatelli, PhD, Anna Guidetti, MD, Loredana Cleris, Silvia Tartari, PhD, Alessandro M. Gianni, MD, Andrea Anichini, PhD, Carmelo Carlo-Stella, MD

Blood (2012) 120 (21): 3711.

https://doi.org/10.1182/blood.V120.21.3711.3711

Published: 2012

Journal Articles

Dual Targeted Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Patients with Relapsed/Refractory Lymphomas: Final Results of a Phase II Trial

Anna Guidetti, MD, Simonetta Viviani, MD, Alfonso Marchianò, MD, Anna Dodero, MD, Lucia Farina, MD, PhD, Silvia L Locatelli, PhD, Domenico Russo, Pietro Bulian, MD, Roberto Sorasio, MD, Massimo Di Nicola, MD, Laura Giordano, MD, Paolo Corradini, MD, Alessandro M. Gianni, MD, Carmelo Carlo-Stella, MD

Blood (2012) 120 (21): 3679.

https://doi.org/10.1182/blood.V120.21.3679.3679

Published: 2012

Journal Articles

LONG-TERM Risk of Late Effects After Treatment for EARLY-STAGE HODGKIN'S Lymphoma (HL).

Simonetta Viviani, MD, Anna DI Russo, MD, Valeria Bonfante, MD, Pinuccia Valagussa, Gianni Bonadonna, MD, Alessandro M. Gianni, MD

Blood (2012) 120 (21): 2732.

https://doi.org/10.1182/blood.V120.21.2732.2732

Published: 2012

Journal Articles

Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses – First Interim Analysis of the GITIL/FIL HD0607 Clinical Trial

Blood (2012) 120 (21): 550.

https://doi.org/10.1182/blood.V120.21.550.550

Published: 2012

Journal Articles

Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study

Blood (2011) 118 (21): 1647.

https://doi.org/10.1182/blood.V118.21.1647.1647

Published: 2011

Journal Articles

Preclinical Rationale for the Use of the Combined Treatment with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Hodgkin Lymphoma

Silvia Locatelli, PhD, Arianna Giacomini, PhD, Anna Guidetti, MD, Loredana Cleris, PhD, Michele Magni, MD, Massimo Di Nicola, MD, Roberta Mortarini, PhD, Alessandro M Gianni, MD, Andrea Anichini, PhD, Carmelo Carlo-Stella, MD

Blood (2011) 118 (21): 1653.

https://doi.org/10.1182/blood.V118.21.1653.1653

Published: 2011

Journal Articles

MiR-146a up-Regulation Is Associated with Anti-Tumor Activity of Pan-Histone Deacetylase Inhibitor ITF2357 (Givinostat®) in Human Burkitt's Lymphoma

Roberta Zappasodi, PhD, Alessandra Cavanè, Marilena V Iorio, Monica Tortoreto, Giusi Ruggiero, Michele Magni, MD, Carmelo Carlo-Stella, MD, Elda Tagliabue, Franco Zunino, Carlo M. Croce, MD, Alessandro M. Gianni, MD, Massimo Di Nicola, MD

Blood (2011) 118 (21): 2729.

https://doi.org/10.1182/blood.V118.21.2729.2729

Published: 2011

Journal Articles

Rituximab Followed by Involved Fields Radiotherapy (IF-RT) in Stage I-II Follicular Lymphoma (FL): Long Term Results,

Marco Ruella, MD, Andrea Filippi, MD, Anna DI Russo, MD, Daniele Caracciolo, MD, Paola Matteucci, MD, Michele Magni, MD, Massimo Di Nicola, MD, Umberto Ricardi, MD, Vittorio Montefusco, MD, Guido Parvis, MD, Corrado Tarella, MD, Alessandro M. Gianni, MD, Liliana Devizzi, MD

Blood (2011) 118 (21): 3699.

https://doi.org/10.1182/blood.V118.21.3699.3699

Published: 2011

NARROW

Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) and Lymphocyte to Monocyte Ratio (LMR) in Newly Diagnosed Advanced-Stage Hodgkin Lymphoma Patients Treated up-Front with a PET-2 Risk Adapted Protocol

Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma

Molecular Definition of Activated B Cell-like (ABC) DLBCL Identifies Patients Who May Benefit from Front-Line Intensive R-HDS Chemotherapy with ASCT

Early Reduction of Serum TARC Levels Predicts Prognosis of Patients Treated with a PET-Adapted Strategy for Advanced Stage Hodgkin Lymphoma (HL) in the GITIL/FIL HD0607 Trial

New Recurrently Mutated Genes in Classical Hodgkin Lymphoma Revealed By Whole-Exome Sequencing of Microdissected Tumor Cells

TARC before ASCT Is Highly Predictive of Outcome in Patients with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) after First-Line Therapy

Late Relapse in Hodgkin Lymphoma (HL): A Retrospective Analysis of Patients Enrolled on Clinical Trials at the Istituto Nazionale Tumori of Milan (INT-MI)

HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma

The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

Brentuximab Vedotin (BV) an Effective Treatment for Autologous (ASCT) and/or Allogeneic (alloSCT) Transplant naïve Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) : A retrospective Single-Institution Study

Potent In Vivo Anti-Tumor Activity Of Extracellular Vesicles Isolated From Genetically Engineered Primary Mesenchymal Stromal Cells Expressing The Trans-Membrane TNF-Related Apoptosis-Inducing Ligand (TRAIL)

The Peripheral Blood Lymphocyte to Monocyte Ratio At Diagnosis Is a Potent Outcome Predictor in Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Long-Term Analysis On 973 Patients Receiving Chemotherapy with or without Rituximab

The histone Deacetylase Inhibitor Givinostat in Combination with Sorafenib Induces Reactive Oxygen Species (ROS) Generation and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts

Dual Targeted Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Patients with Relapsed/Refractory Lymphomas: Final Results of a Phase II Trial

LONG-TERM Risk of Late Effects After Treatment for EARLY-STAGE HODGKIN'S Lymphoma (HL).

Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses – First Interim Analysis of the GITIL/FIL HD0607 Clinical Trial

Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study

Preclinical Rationale for the Use of the Combined Treatment with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Hodgkin Lymphoma

MiR-146a up-Regulation Is Associated with Anti-Tumor Activity of Pan-Histone Deacetylase Inhibitor ITF2357 (Givinostat®) in Human Burkitt's Lymphoma

Rituximab Followed by Involved Fields Radiotherapy (IF-RT) in Stage I-II Follicular Lymphoma (FL): Long Term Results,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only